Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it will host a dedicated analyst and investor event centered on lacutamab, a promising therapy in the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). The event, designed to provide an in-depth overview of both the clinical and commercial perspectives surrounding lacutamab, is scheduled to take place on Tuesday, October 28, 2025, from 8:00 a.m. to 10:00 a.m. Eastern Time (ET) / 1:00 p.m. to 3:00 p.m. Central European Time (CET) at the Park Terrace Hotel on Bryant Park, New York. Participants will have the option to attend either in person or virtually.
This event underscores Innate Pharma’s commitment to engaging with the investor community and providing detailed insights into lacutamab’s development pathway, particularly its potential for accelerated approval in Sézary syndrome based on robust long-term follow-up data from the Phase 2 TELLOMAK trial. The company intends to share clinical results, regulatory updates, and market analyses, offering attendees a comprehensive understanding of the therapy’s potential impact on patient outcomes and the oncology market.
Event Program and Key Speakers
The program will feature Pierluigi Porcu, M.D., a globally recognized expert in T-cell lymphomas and Division Chief for Hematology and Blood and Marrow Transplantation (BMT) at the University of Kentucky, Lexington. Dr. Porcu will present a detailed medical perspective on the results from the Phase 2 TELLOMAK study, which evaluated lacutamab in patients with relapsed or refractory (R/R) CTCL, including Sézary syndrome and advanced mycosis fungoides. His presentation will cover clinical efficacy, safety outcomes, and observed improvements in patient quality of life, providing critical context for the therapy’s ongoing development.
Complementing the clinical overview, ZS Associates, a leading consulting firm specializing in life sciences and healthcare markets, will provide an analysis of the eligible U.S. CTCL patient population. Drawing from real-world claims data, ZS Associates will highlight patient demographics, prevalence, and treatment patterns, giving investors a clear picture of lacutamab’s potential market opportunity.
Finally, Innate Pharma’s management team will provide strategic updates on the planned Phase 3 trial in CTCL, the regulatory pathway toward accelerated approval, and the anticipated commercial potential of lacutamab. This session will also cover the company’s overall development strategy for lacutamab and its positioning within the broader T-cell lymphoma treatment landscape. The event will conclude with a live Q&A session, allowing attendees to engage directly with Innate Pharma executives and the featured experts.
Leadership Commentary
Jonathan Dickinson, Chief Executive Officer of Innate Pharma, commented on the upcoming event:
We look forward to engaging with the investor community in New York to share the latest updates and perspectives on lacutamab, a product that has the potential to meaningfully improve outcomes and quality of life for CTCL patients with significant unmet medical needs, while creating substantial value for our shareholders. Supported by strong Phase 2 TELLOMAK results, lacutamab is well positioned for accelerated approval in Sézary syndrome once the confirmatory Phase 3 study is underway. Moreover, new real-world data highlighting a larger eligible CTCL population in the U.S. reinforces our commitment to advancing lacutamab for patients. The Phase 3 protocol is nearing completion, marking an important milestone in our development program.”
Registration and Access
Investors and analysts interested in attending the event, either in person or virtually, can register through Innate Pharma’s investor relations portal. A replay of the event will be made available on the company’s website for those unable to participate live.
About Pierluigi Porcu, M.D.
Dr. Pierluigi Porcu is the Ewa Marciniak Endowed Chair Professor and Division Chief for Hematology and BMT at the University of Kentucky College of Medicine. He also serves as Associate Director for Clinical Translation at the UK Lucille P. Markey Comprehensive Cancer Center. An NCI-funded physician-scientist, Dr. Porcu is internationally recognized for his work in clinical and translational research in T-cell lymphomas. He has previously served as President of the United States Cutaneous Lymphoma Consortium (USCLC) and is a member of the board of directors of the International Society of Cutaneous Lymphomas (ISCL).
Throughout his Innate Pharma career, Dr. Porcu has contributed to numerous advisory boards and clinical trial steering committees, serving as a global coordinating investigator or chair. He earned his medical degree from the University of Torino in Italy and completed his residency in internal medicine and fellowship in hematology-oncology at Indiana University, Indianapolis. From 1999 to 2015, Dr. Porcu was a faculty member in the Division of Hematology at The Ohio State University. From 2016 to 2025, he served as Professor and Division Director of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation in the Department of Medical Oncology at Thomas Jefferson University, Philadelphia.
About Lacutamab
Lacutamab is a first-in-class monoclonal antibody targeting KIR3DL2, a receptor overexpressed on malignant T-cells in CTCL and PTCL. The therapy is under investigation for the treatment of rare and aggressive forms of CTCL, including Sézary syndrome and advanced mycosis fungoides. Sézary syndrome is a leukemic variant of CTCL associated with poor prognosis, while mycosis fungoides is the most common subtype, with advanced stages also linked to limited treatment options and poor outcomes.
The Phase 2 TELLOMAK trial demonstrated that lacutamab is associated with durable clinical activity, a favorable safety profile, and meaningful improvements in patient quality of life. The trial’s long-term follow-up data has informed Innate Pharma’s discussions with regulatory agencies and provided the foundation for the therapy’s proposed path toward Accelerated Approval in Sézary syndrome.
Innate Pharma Regulatory agencies have recognized lacutamab’s potential in addressing significant unmet medical needs. The therapy has received Fast Track designation from the U.S. Food and Drug Administration (FDA), PRIME designation from the European Medicines Agency (EMA) for Sézary syndrome, and Orphan Drug designation in both the U.S. and EU for CTCL. Most recently, lacutamab was granted Breakthrough Therapy Designation for Sézary syndrome, underscoring its potential as a transformative therapy for this patient population.
A confirmatory Phase 3 trial in CTCL is currently in preparation, with the protocol nearing completion. This pivotal study is expected to provide the data necessary to support potential regulatory approvals and further demonstrate lacutamab’s clinical benefit in patients with relapsed or refractory disease.
Commercial and Market Potential
The upcoming analyst and investor event will provide attendees with a detailed overview of lacutamab’s commercial potential. ZS Associates will present real-world data highlighting a larger eligible patient population in the United States than previously reflected in public datasets. These insights are expected to inform market projections and underscore the broader opportunity for lacutamab in CTCL treatment.
Innate Pharma management will outline the company’s strategic approach to commercialization, including anticipated pricing, patient access considerations, and the potential for early uptake in key markets. By combining clinical efficacy, favorable safety, and a clear regulatory path, lacutamab represents a significant step forward in addressing the unmet needs of CTCL patients while offering meaningful value creation for investors.
Innate Pharma’s October 28, 2025, analyst and investor event represents a pivotal moment in the development of lacutamab. The program will provide a comprehensive view of the therapy’s clinical performance, regulatory trajectory, and commercial potential, supported by insights from leading experts in T-cell lymphoma and life sciences market analytics. With strong Phase 2 results, ongoing regulatory engagement, and preparation for a confirmatory Phase 3 study, lacutamab is poised to become a key therapy in the treatment of CTCL, offering hope to patients with limited options and high unmet needs.
Investors, analysts, and other stakeholders are encouraged to register for the event to gain first-hand insights into the progress and prospects of lacutamab. A replay of the event will be available through Innate Pharma’s investor relations website following the live session.
